Loading...
XHKG
2877
Market cap823mUSD
Dec 05, Last price  
8.49HKD
1D
-0.12%
1Q
-2.19%
Jan 2017
-3.52%
IPO
80.64%
Name

China Shineway Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
XHKG:2877 chart
P/E
6.93
P/S
1.54
EPS
1.11
Div Yield, %
6.84%
Shrs. gr., 5y
-0.66%
Rev. gr., 5y
6.90%
Revenues
3.78b
-16.35%
831,379,000841,475,0001,012,885,0001,275,179,0001,633,223,0002,038,379,0001,984,542,0002,132,249,0002,187,115,0002,229,201,0002,054,809,0001,993,379,0001,919,608,0002,570,196,0002,705,996,0002,655,701,0003,223,550,0003,950,636,0004,516,538,0003,778,043,000
Net income
840m
-13.35%
337,006,000332,977,000490,641,000398,242,000767,304,000821,756,000755,600,000647,704,000683,647,000704,775,000657,906,000589,196,000451,553,000505,876,000503,150,000295,033,000556,674,000722,773,000969,510,000840,052,000
CFO
963m
+3.27%
457,646,000417,409,000401,970,000405,280,0001,057,320,000579,425,000485,062,000635,673,000519,885,999773,158,000744,707,000733,526,000490,646,000532,586,000367,996,000638,566,000703,150,0001,109,676,000932,635,000963,135,000
Dividend
Sep 10, 20240.12 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.
IPO date
Dec 02, 2004
Employees
4,131
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT